Lymphokine Patents (Class 424/85.1)
  • Patent number: 10293034
    Abstract: Disclosed herein is a liquid pharmaceutical composition of botulinum toxin which is improved in stability. It comprises botulinum toxin, polysorbate 20, and methionine and optionally isoleucine. Employing, instead of the animal-derived protein albumin or gelatin, a combination of polysorbate 20 and methionine and optionally isoleucine as botulinum toxin stabilizers, the liquid pharmaceutical composition eliminates the risk of contaminating the body with serum-derived pathogens or microorganisms and can be administered safely to the body. Also, the composition is convenient for use as a direct injection for patients. Superior to conventional compositions employing either detergents or amino acids in terms of the storage stability of botulinum toxin at 25˜37° C. as well as at refrigerated temperatures, the liquid pharmaceutical composition of the present invention is very useful for storing botulinum toxin under an emergency condition such as an environment without maintaining low temperature.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: May 21, 2019
    Assignee: Medy-Tox, Inc.
    Inventors: Hyun Ho Jung, Gi Hyeok Yang, Hack Woo Kim, Hee Dong Woo, Chang Hoon Rhee
  • Patent number: 10265412
    Abstract: The present invention relates in general to the field of enzyme replacement therapy, and specifically to chimeric proteins including protein hormone-therapeutic protein conjugates and fusion proteins, wherein the protein hormone is selected from a protein hormone which is able to cross the blood brain barrier, for the treatment of lysosomal storage diseases, compositions of the same and to methods of use thereof.
    Type: Grant
    Filed: February 6, 2007
    Date of Patent: April 23, 2019
    Assignees: Ramot at Tel-Aviv University Ltd., Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science, The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center
    Inventors: Naftali Stern, Ruth Navon, Anthony Futerman, Ari Zimran, Etty Osher
  • Patent number: 10245281
    Abstract: Heparan sulphate HS7 is disclosed, together with the use of HS7 in the growth and/or development and/or regeneration of tissue.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: April 2, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Simon Cool, Victor Nurcombe
  • Patent number: 10183093
    Abstract: A wound dressing composition comprising a non-viable cell lysate or releasate derived from a hepatocyte cell or an inflammatory cell such as a macrophage. Also provided are wound dressings comprising such compositions, methods of making such compositions, and the use of such compositions for the treatment of wounds.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: January 22, 2019
    Assignee: KCI USA, INC.
    Inventors: Rachael Louise McInnes, Breda Mary Cullen, Lindsay Page
  • Patent number: 10180433
    Abstract: The present invention is related to a method for detecting a protein comprising: (1) providing a fusion protein, wherein the fusion protein comprises the protein which is fused with a secondary antibody detected protein tag, wherein the secondary antibody detected protein tag comprises at least one epitope selected from the Fc region of at least one primary antibody which is capable of being detected by a corresponding secondary antibody; (2) contacting the fusion protein with a secondary antibody which binds to the secondary antibody detected protein tag to form a protein/antibody complex; and (3) detecting the protein/antibody complex.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: January 15, 2019
    Inventors: Tian-Lu Cheng, Steve Roffler, Wen-Wei Lin, I-Ju Chen
  • Patent number: 10137109
    Abstract: Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: November 27, 2018
    Assignee: INCURON, INC.
    Inventors: John Tucker, Sergey Sviridov, Leonid Brodsky, Catherine Burkhart, Andrei Purmal, Katerina Gurova, Andrei Gudkov
  • Patent number: 10123985
    Abstract: Provided herein are methods, compositions, and systems for treating mitochondrial disorders (e.g., MERRF, MELAS, Kearns-Sayre syndrome, chronic progressive external ophthalmoplegia, diabetes mellitus and deafness, lactic acidosis, Leber's hereditary optic neuropathy, Wolff-Parkinson-White syndrome, Leigh syndrome, NARP, myoneurogenic gastrointestinal encephalopathy, mitochondrial DNA depletion syndrome) or neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease) by administering aspartate, or an analog or prodrug thereof, or an agent that increases intracellular levels of aspartate. Pharmaceutical compositions and kits for use in treating mitochondrial disorders and neurodegenerative diseases are also described herein. Also provided are methods for treating disease by modulating the redox state of a cell, and methods of treating a proliferative disease by administering a cytosolic aspartate aminotransferase (GOT1) inhibitor.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: November 13, 2018
    Assignees: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Howard Hughes Medical Institute
    Inventors: David M. Sabatini, Kivanc Birsoy, Matthew George Vander Heiden, Lucas Bryan Sullivan, Dan Yi Gui
  • Patent number: 10092597
    Abstract: Graft-versus-host disease (GVHD) is a lethal complication of allograft transplantation. The current strategy of using immunosuppressive agents to control GVHD may cause general immune suppression and limit the effectiveness of allograft transplantation. Adoptive transfer of regulatory T cells (Treg) can prevent GVHD in rodents, indicating the therapeutic potential of Treg for GVHD in humans. However, the clinical application of Treg-based therapy is hampered by the low frequency of human Treg and the lack of a reliable model to test their therapeutic effects in vivo. Human alloantigen-specific Treg are generated from antigenically-naïve precursors in a large scale ex vivo using allogeneic activated B cells as stimulators. Here, a human allogeneic GVHD model is established in humanized mice to mimic GVHD after allograft transplantation in humans.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: October 9, 2018
    Inventors: Wenwei Tu, Yinping Liu, Jian Zheng
  • Patent number: 10071158
    Abstract: The present invention relates to methods for reducing or eliminating the non-specific release of a cytokine associated with a disease comprising administering at least one glucocorticoid and an immunostimulating antibody. Additionally, the present invention relates to a pharmaceutical composition that contains at least one immunostimulating antibody and at least one glucocorticoid.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: September 11, 2018
    Inventors: Markus M. Heiss, Horst Lindhofer
  • Patent number: 10036752
    Abstract: The invention provides a method of determining the colorectal cancer status of subject, comprising applying to a colon and/or rectal surface an agent which is able to distinguish between a) mature glycosylated forms of MUC2 and b) incomplete or aberrant glycosylated forms of MUC2, and determining the extent to which the agent binds.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: July 31, 2018
    Assignee: Oxford University Innovation Limited
    Inventor: Trevor Ming-Yee Yeung
  • Patent number: 10028951
    Abstract: This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: July 24, 2018
    Inventors: Zhigang Xiong, Roger P. Simon
  • Patent number: 10016524
    Abstract: The invention provides a solution to the drawbacks associated with conventional alginate dressings. This invention features improved alginate dressings or bandages as well as a fabrication process that results in an alginate sheet that is preloaded with drug, can be stored in a freeze-dried state, and is compliant and ready to use at the time of administration.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: July 10, 2018
    Assignees: President and Fellows of Harvard College, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Cathal J. Kearney, Uyanga Tsedev, David J. Mooney, Aristidis Veves, Thomas Michael Braschler, Sidi A. Bencherif
  • Patent number: 10016416
    Abstract: This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: July 10, 2018
    Inventors: Zhigang Xiong, Roger P. Simon
  • Patent number: 9990716
    Abstract: In a method for visualization of scar tissue in medical imaging data of a heart, medical imaging data representing a heart myocardium and scar tissue within the heart myocardium are obtained and provided to a computer. The computer deviates the thickness of the myocardium into a number of layers and calculates the presence and distribution of scar tissue within each of the layers. The scar tissue is shown in a visualization of the myocardium; and a user is provided with controls to allow the user to select which of the layers of scar tissue is visualised.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: June 5, 2018
    Assignee: Siemens Healthcare GmbH
    Inventors: Peter Mountney, Sabrina Reiml, Daniel Toth, Alexander Brost, Maria Panayiotou, Kawal Rhode
  • Patent number: 9974288
    Abstract: The present invention provides to a polyethylene glycol-modified feline-derived protein which is obtained by chemically modifying a feline-derived protein with polyethylene glycol. The feline-derived protein is produced by a method comprising any or a combination of extracting the protein from somatic cells of a transgenic bird and/or an egg laid thereby, purifying and activating the same. The transgenic bird has a foreign gene containing a sequence encoding a feline-derived protein.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: May 22, 2018
    Assignee: Kaneka Corporation
    Inventors: Tomoyuki Nakaishi, Takuya Shindo, Tomoko Awa
  • Patent number: 9976147
    Abstract: Described herein, inter alia, are STAT-binding nucleic acids-including compositions and methods of using the same.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: May 22, 2018
    Assignee: City of Hope
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski
  • Patent number: 9950014
    Abstract: Methods for treating or preventing preeclampsia or eclampsia by administering adherent stromal cells are described. The adherent stromal cells may be derived from bone marrow, placenta, or adipose tissue. Also described is the use of adherent stromal cells for the manufacture of a medicament, and an article of manufacture comprising a packaging material which comprises a label for use in treating or preventing preeclampsia or eclampsia.
    Type: Grant
    Filed: August 31, 2013
    Date of Patent: April 24, 2018
    Assignee: PLURISTEM LTD.
    Inventors: Ayelet Chajut, Eytan Abraham
  • Patent number: 9938355
    Abstract: Antibodies, and antigen-binding fragments, which specifically bind to argininosuccinate synthase, and related compositions, kits, and methods of use, which are useful as companion diagnostics to identify suitable subjects for arginine deprivation or depletion therapies such as ADI-PEG 20 and other arginine deiminase (ADI) polypeptide-based therapies.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: April 10, 2018
    Assignee: TDW Group
    Inventors: Wei He, Yunyun Guo, Bor-Wen Wu
  • Patent number: 9931386
    Abstract: The invention relates to cell stimulatory fusion proteins and DNA sequences, vectors comprising at least two agonists of TNF/TNFR super family, immunoglobulin super family, cytokine family proteins and optional antigen combination. Instructions for use of these proteins and DNA constructs as immune adjuvants and vaccines for treatment of various chronic diseases such as viral infection are also provided. Additionally, the use of these protein and DNA constructs as immune suppressant for treatment of various chronic diseases, such as autoimmunity and organ transplant rejection, is also illustrated.
    Type: Grant
    Filed: June 12, 2009
    Date of Patent: April 3, 2018
    Inventor: Atsuo Ochi
  • Patent number: 9926352
    Abstract: A chimeric protein that is a fusion construct of a series of functional domains is used to deliver a therapeutic agent to a human subject suffering from disease. In some embodiments, the chimeric protein includes a therapeutic region, a transportation region, and a cleavage region disposed between the therapeutic region and the transportation region. The transportation region allows the chimeric protein to be moved across a cellular membrane of an affected cell within the subject. Cleavage of the chimeric protein at the cleavage region once within the cell separates the therapeutic region from the transportation region, enabling the therapeutic region to function normally within the cell. The therapeutic region can be effective in the treatment of, for example, muscular dystrophy, diastrophic dysplasia, malignant melanoma, porphyria, alpha-1 antitrypsin deficiency, Aicardi-Goutieres syndrome, cystic fibrosis, progeria, Marfan syndrome, tuberous sclerosis, adrenoleukodystrophy, and the like.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: March 27, 2018
    Inventor: Sujata Acharjee
  • Patent number: 9913879
    Abstract: The inventive subject matter relates to novel methods for modulating an immune response in an animal, which comprises administering to said animal an effective amount of an agent that increases IL-27R/WSX-1 activity. Further, the inventive subject matter relates to pharmaceutical compositions comprising an effective amount of an agent that increases IL-27R/WSX-1 activity.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: March 13, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Christopher A. Hunter, Alejandro Villarino
  • Patent number: 9907829
    Abstract: The present invention relates to stable aqueous formulations comprising at least 5 mg/mL CD-RAP and a charged amino acid, said amino acid preferably having a net charge at a pH between about 6 and 8. The ingredients of the formulation preferably provide stability over repeated freeze-thaw cycles. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory disorders, preferably osteoarthritis. Furthermore, a kit comprising the formulation of the invention is provided.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: March 6, 2018
    Inventors: Klaus Hellerbrand, Rainer Sigl
  • Patent number: 9901628
    Abstract: The application discloses therapeutic vaccines based upon the “pING” DNA plasmid vector expressing the gene encoding the rat Her2 protein. Vaccines according to the instant disclosure are used as an adjunct treatment for surgery, radiation and/or chemotherapy for dogs and cats with cancers that over express the Her2 antigen, and prolong the post-surgical disease free interval and/or survival time. Also included are therapeutically effective methods of immunization using said vaccines.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: February 27, 2018
    Assignee: MERIAL INC.
    Inventor: Laurent Bernard Fischer
  • Patent number: 9901644
    Abstract: A prodrug is provided which includes at least two different pharmaceutically and/or diagnostically active compounds independently bound by cleavable linkers and a protein-binding moiety which is capable of binding to carrier a molecule.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: February 27, 2018
    Assignee: KTB Tumorforschungsgesellschaft mbH
    Inventors: Felix Kratz, Irmgard Merfort
  • Patent number: 9895321
    Abstract: Methods and products for treating and/or delaying onset of dysplastic lesions, and wafers for oral administration employ dry powder compositions including myo-inositol. Methods for administering a vaccine for a virus or bacteria to an individual comprising administering a first portion of the vaccine to the individual via one route and administering a second portion via a second, different route. In a specific embodiment, the first route is sublingually. Vaccines are provided in the form of dry powder compositions comprising a combination of nanoparticles and microparticles, or in the form of a wafer which dissolves in water at room temperature in less than about one minute. Storage stable unit dosages of a vaccine are provided by individually packaging individual unit dosages of a dry powder composition comprising the vaccine and a carrier in blister compartments formed of gas and moisture resistant material.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: February 20, 2018
    Assignee: AKTIV-DRY LLC
    Inventors: Robert E. Sievers, Stephen P. Cape, David McAdams, J'aime Manion, Pankaj Pathak
  • Patent number: 9890432
    Abstract: The invention relates to method for detecting HPV-induced high-grade precancerous lesions and HPV-induced invasive cancers, said method comprising detection of hypermethylation in the PRDM14 and/or FAM19A4 gene in a cell whereby such hypermethylation indicates the presence of HPV-induced precursor lesions with invasive potential and HPV-induced invasive cancers. The invention further comprises the use of the PRDM14 and/or FAM19A4 gene in such a method and a testkit for the detection of PRDM14 and/or FAM19A4 methylation.
    Type: Grant
    Filed: October 14, 2013
    Date of Patent: February 13, 2018
    Assignee: SELF-SCREEN B.V.
    Inventors: Christophorus Joannes Lambertus Maria Meijer, Petrus Josephus Ferdinandus Snijders, Renske Daniëla Maria Steenbergen
  • Patent number: 9867804
    Abstract: Embodiments provide methods for using ascorbate for the stimulation of production of elastic fibers by cells.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: January 16, 2018
    Assignees: Human Matrix Sciences, LLC, The Hospital for Sick Children
    Inventors: Thomas F. Mitts, Aleksander Hinek, Hyunjun Jonathan Kim
  • Patent number: 9861705
    Abstract: Conjugates of an interleukin-2 (“IL-2”) moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, methods of administering compositions to an individual, nucleic acid sequences, expression systems, host cells, and methods for preparing IL-moieties.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: January 9, 2018
    Assignee: Nektar Therapeutics
    Inventors: Mary J. Bossard, Cherie F. Ali, Xiaofeng Liu, Deborah H. Charych, Yujun Wang
  • Patent number: 9855370
    Abstract: Methods for increasing the patency of biodegradable, synthetic vascular grafts are provided. The methods include administering one or more cytokines and/or chemokines that promote outward tissue remodeling of the vascular grafts and vascular neotissue formation. The disclosed methods do not require cell seeding of the vascular grafts, thus avoiding many problems associated with cell seeding. Biodegradable, polymeric vascular grafts which provide controlled release of cytokines and/or chemokines at the site of vascular graft implantation are also provided.
    Type: Grant
    Filed: January 8, 2009
    Date of Patent: January 2, 2018
    Assignee: Yale University
    Inventors: Christopher Breuer, Themis Kyriakides, Jason Roh
  • Patent number: 9839670
    Abstract: This document provides novel compositions and methods utilizing immunomodulating agents that can stimulate or indirectly augment the immune system, or can have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, e.g., to treat disease caused by asthma and chronic inflammation, such as inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein can inhibit CD8 T cell-mediated cellular immune responses and can, for example, mitigate organ or tissue rejection following a tissue transplantation. TNFR25 agonists disclosed herein represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to boost, direct, or restore the body's ability to fight the cancer when given with tumor vaccines.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: December 12, 2017
    Inventors: Eckhard R. Podack, Vadim Deyev, Robert Levy
  • Patent number: 9821028
    Abstract: Disclosed herein are methods of controlling parasitic worms in herbivorous mammals and other species by orally administering an isolated antibody that specifically binds the interleukin-10 peptide or an interleukin-10 peptide. In the case of herbivorous mammals such as cattle, for example, administration of the anti-IL-10 antibodies increases weight gain and increases feed efficiency in the animals.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: November 21, 2017
    Inventors: Mark Eric Cook, Daniel Meilahn Schaefer, Mitchell Raymond Schaefer, Jordan Marshall Sand, Larry Smith
  • Patent number: 9789200
    Abstract: The present invention describes the new use in the oncologic field of bioconjugates as differentiating agents obtained by the conjugation between hyaluronic acid (HA) and a chemotherapeutic product (identified hereafter with the trade-name ONCOFID®) among which, in particular, Irinotecan, Doxorubicin, Paclitaxel, Cis-platinum and 5-Fluorouracyl (5-FU) for treating primary tumors and metastasis. In particular, the biological behavior is described in terms of action mechanism, efficacy and tolerability of pharmaceutical preparations of derivative of ONCOFID® soluble in water. More specifically, the invention relates to the surprising biological and pharmacological effect demonstrated by formulations based on ONCOFID-S (HA-SN38 conjugates) and ONCOFID-D (HA-Doxorubicin conjugates) in promoting the differentiation of tumoral cells towards a untransformed phenotype, compared with the reference drug Irinotecan (or CPT11 whose active form is represented by SN38) and Doxorubicin.
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: October 17, 2017
    Inventors: Monica Campisi, Davide Renier, Pasquale Pierimarchi, Annalucia Serafino
  • Patent number: 9782432
    Abstract: Certain embodiments of the invention provide a copolymer having a backbone, wherein the backbone comprises a) one or more units that comprise a group that will yield a biologically active agent upon hydrolysis of the backbone; and b) one or more units of formula (II): wherein y is 1 or more. Other embodiments of the invention provide a therapeutic method for treating a wound in an animal comprising administering to an animal in need of such therapy, an effective amount of a copolymer as described herein.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: October 10, 2017
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Kathryn E. Uhrich, Sabrina S. Snyder
  • Patent number: 9782345
    Abstract: An ocular composition can include a polymer matrix and an antibiotic dispersed in the polymer matrix. The polymer matrix can contain a thiolated hyaluronic acid moiety cross-linked to a second moiety. The composition can be configured for placement in or on an eye of a subject to provide controlled release of the antibiotic to the eye. A method of treating or preventing an ocular disease can include providing an ocular composition and applying the ocular composition to a surface of an eye of a subject to provide controlled release of the antibiotic to the eye. The ocular composition can include a polymer matrix and an antibiotic dispersed in the polymer matrix. The polymer matrix can include a thiolated hyaluronic acid moiety cross-linked to a second moiety.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: October 10, 2017
    Assignee: Jade Therapeutics, Inc.
    Inventor: Barbara Wirostko
  • Patent number: 9763980
    Abstract: The present embodiments provide for combinations of modulators that increase hematopoietic stem cell engraftment or increase mobilization in vivo. Methods and compositions for modulating the mobilization of stem cells, particularly for promoting or increasing the mobilization of hematopoietic stem cells (HSCs) from the bone marrow to the peripheral blood are disclosed. One aspect of the invention relates to the use of a CXCR4 antagonist that act in concert with specific molar ratios of S1P receptor 1 (S1PR1) modulator agents to promote HSC mobilization. The invention also relates to methods of using these combinations of CXCR4 antagonists and S1PR1 modulator agents for enhancing the mobilization of hematopoietic stem cells when harvesting of the stem cells, for example for the treatment of diseases, disabilities or conditions whereby transplantation of such cells would be beneficial in ameliorating a symptom associated with such diseases, disabilities or conditions.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: September 19, 2017
    Assignee: Children's Medical Center Corporation
    Inventors: Leonard I Zon, Owen J. Tamplin
  • Patent number: 9745351
    Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the truncated L1 protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: August 29, 2017
    Inventors: Shaowei Li, Huirong Pan, Bo Liu, Jun Zhang, Ji Miao, Ningshao Xia
  • Patent number: 9737613
    Abstract: The invention relates to colloids bound medicinal compounds or fluorescent markers, to a process for the preparation thereof, and to a pharmaceutical formulation containing such compounds.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: August 22, 2017
    Assignee: B. Braun Melsungen AG
    Inventors: Helmut Rosemeyer, Edith Malecki
  • Patent number: 9738696
    Abstract: Disclosed herein are IL-4 cytokine compositions with enhanced biological activity having increased selectivity for IL-4 cytokine receptors, and methods for their use. These compositions encompass interleukin-4 (IL-4) muteins. The disclosed methods encompass administering an IL-4 to treat neoplastic diseases, autoimmune diseases, infectious diseases or for expanding a hematopoietic cell population.
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: August 22, 2017
    Inventors: K. Christopher Garcia, Darren L. Bates, Ignacio Moraga
  • Patent number: 9730906
    Abstract: Alpha-derivatives of cis-monounsaturated fatty acids for use as medicines. The present invention refers to pharmaceutically acceptable compounds of Formula I, their salts and derivatives, where (a) and (b) can take any value between 0 and 14, (X) can be substituted by any atom or group of atoms with an atomic/molecular weight between 4 and 200 Da and (R) can be substituted by any atom or group of atoms with an atomic/molecular weight between 1 and 200 Da, for use as medicines.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: August 15, 2017
    Inventors: Pablo Vicente Escribá Ruiz, Xavier Busquets Xaubet, Gwendolyn Barceló Coblijn, Victoria Lladó Cañellas, Rafael Álvarez Martínez, Silvia Teres Jiménez, Daniel López, Juana Barceló Estarellas, Julian Taylor Green, Gerardo Ávila Martín
  • Patent number: 9730434
    Abstract: Methods of generating modified embryos and mammals by introduction of donor cells into an early stage embryo are provided, such that the resulting embryo and animal generated therefrom has a significant contribution to all tissues from the donor cells and is capable of transmitting the donor cell DNA.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: August 15, 2017
    Inventors: William Poueymirou, Thomas M. DeChiara, Wojtek Auerbach, David Frendewey, David M. Valenzuela
  • Patent number: 9718870
    Abstract: The disclosure provides OX40L huIgG4 fusion polypeptide subunits comprising a human IgG4 Fc domain, a trimerization domain, and the receptor binding domain of Ox40 ligand, where the fusion polypeptide subunits can self-assemble into hexameric proteins. Also provided are methods of making fusion polypeptide subunits and hexameric proteins, and methods of use, e.g., treatment of cancer.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: August 1, 2017
    Assignee: MedImmune, LLC
    Inventors: Melissa Damschroder, Michael Oberst, Scott Hammond, Hui Feng
  • Patent number: 9693951
    Abstract: An elongate body for parenteral injection at low velocity from a device is described. The body has at least one pointed end and comprises at least one active material. In addition, the body has a compressive strength of greater than or equal to 5 Newton and the pointed end has an included angle of between about 10-50°. A solid vaccine formulation for needle-free parenteral delivery, methods for making the body, packaging of the body and use of the body, packaging and suitable delivery device are also described.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: July 4, 2017
    Inventors: Charles David Ogilvy Potter, Shohre Nabahi
  • Patent number: 9688611
    Abstract: A method for producing a compound of formula (I) or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer, such as compound 1 and compound 2 is disclosed. The method proceeds through an O-allylated tyrosine-based compound, such as compound 3 and preferably comprises [3,3] sigmatropic Claisen rearrangement and olefin cross metathesis reactions. In addition, a pharmaceutical composition comprising a compound of formula (I) a tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) and a pharmaceutically acceptable carrier or excipient is disclosed.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: June 27, 2017
    Assignee: King Fahd University of Petroleum and Minerals
    Inventors: Muhammad Mansha, Yasir Abbas, Nisar Ullah
  • Patent number: 9649377
    Abstract: This invention relates to methods employing IL-1?-ligand/IL-1 receptor disrupting compounds such as IL-1? antibodies or IL-1 receptor antibodies, in the treatment and/or prevention of Familial Mediterranean Fever (FMF), in mammals, particularly humans.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: May 16, 2017
    Assignee: Novartis AG
    Inventors: Philip Lowe, Hermann Gram, Thomas Jung, Timothy Wright, Trevor Mundel
  • Patent number: 9636412
    Abstract: Conjugates of an anti-TNF antibody and one or more nonpeptidic water soluble polymers are provided. Typically, the nonpeptidic water soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to a patient.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: May 2, 2017
    Assignee: Nektar Therapeutics
    Inventors: Mary J. Bossard, Gayle Stephenson-Phillips
  • Patent number: 9632075
    Abstract: Methods of reducing or abolishing neuropathic pain in humans and animals are discussed. In some examples administration of the apoptosis inhibitor tauroursodeoxycholic acid (TUDCA), greatly reduced both neuronal loss and the increase in glia, and partially reversed spinal nerve ligation (SNL)-induced mechanical hypersensitivity. Among RVM neurons, serotonergic (5-HT) neurons decreased by 35% ipsilateral to SNL. In some examples, the density of 5-HT immunoreactive varicosities in the superficial dorsal horn of the spinal cord was lower ipsilateral to SNL. The RVM 5-HT neurons that remained after SNL appeared to facilitate nociception. When rats that had undergone SNL were treated with the 5-HT neurotoxin, 5,7-dihydroxytryptamine (5,7-DHT), mechanical withdrawal thresholds increased significantly. In some examples nerve injury induces death of antinociceptive RVM neurons which can be reduced or abolished by TUDCA.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: April 25, 2017
    Assignee: Meselex, Inc.
    Inventors: Mai Lan Leong, Clifford Steer, Martin Wessendorf
  • Patent number: 9617531
    Abstract: The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: April 11, 2017
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
  • Patent number: 9611306
    Abstract: Certain embodiments are directed to novel heterotrimeric fusions in which the ectodomain of the TGF-? type II receptor (T?P?II) is coupled to the N- and C-terminal ends of the endoglin-domain of the TGF-? type III receptor (TpRIIIE). Certain embodiments are directed to novel heterotrimeric polypeptides in which the ectodomain of the TGF-? type II receptor (TI3RII) is coupled to the N- and C-terminal ends of the endoglin-domain (E domain) of the TGF-? type III receptor (TI3RIII). This trimeric receptor, known as RER, can bind all three TGF-? isoforms with sub-nanomolar affinity and is effective at neutralizing signaling induced by all three TGF-? isoforms, but not other ligands of the TGF-? superfamily, such as activins, growth and differentiation factors (GDFs), and bone morphonogenetic proteins (BMPs).
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: April 4, 2017
    Inventors: Andrew Hinck, Luzhe Sun, Christian Zwieb
  • Patent number: 9566341
    Abstract: The presently-disclosed subject matter includes compounds including a cyclooxygenase enzyme inhibitor moiety and a moiety derived from a drug of interest. In some embodiments, the drug of interest is an opioid. In some embodiments, the compound includes a diclofenac moiety and a naltrexone or naltrexol moiety. The compounds allow for enhanced delivery rates across skin.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: February 14, 2017
    Assignee: University of Kentucky Research Foundation
    Inventors: Audra Stinchcomb, Kyung Bo Kim, Ragotham Reddy Pinninti, Priyanka Ghosh, Kalpana S. Paudel
  • Patent number: 9561289
    Abstract: A product comprising a peptide that comprises a motif selected from a group consisting of isoDGR, NGR and DGR, wherein the peptide cyclized by joining the N- and C-termini of its main chain and wherein the cyclic peptide is joined to albumin.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 7, 2017
    Inventors: Angelo Corti, Flavio Curnis